Kerecis is involved in developing and producing a tissue-regeneration materials including MariGen Omega3, which is derived from fish skin to accelerate the healing of wounds and tissue reconstruction.

MariGen Omega3 product, which is manufactured according to a patent-pending method, contains Omega3 and other fish skin components, with all its cells and antigenic materials removed leaving behind extra-cellular matrix and looks like fish skin.

Under the agreement, Medline will initially sell products that utilize the MariGen Omega3 regenerative technology for the management of chronic wounds, including diabetic, vascular and other hard-to-heal wounds, in the UK and several Middle Eastern countries.

Kerecis is also planning to develop products to treat chronic wounds, hernias and defects in dura mater after neurosurgery.